Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated <i>ERBB2</i>-Positive Esophagogastric Adenocarcinoma
Alexander Stein(Universität Hamburg), Mascha Binder(Universität Hamburg), Eray Goekkurt(Sorbonne Université), Lisa Paschold, Wolfgang Hiegl(AIO Studien gGmbH), Joseph Tintelnot(Universität Hamburg), Donjetë Simnica(University Hospital in Halle), Anke Reinacher‐Schick(Ruhr University Bochum), Lutz Jacobasch(Orthopädische Praxis), Daniel Pink(Universitätsmedizin Greifswald), Stefan Kubicka(Medizinische Hochschule Hannover), Christoph Schultheiß(University Hospital of Basel), Susanna Hegewisch‐Becker, Jorge Riera‐Knorrenschild, Marcus Bauer, Thomas J. Ettrich(Universität Ulm), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Edith Willscher(Martin Luther University Halle-Wittenberg), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Udo Lindig(Jena University Hospital), Svenja-Sibylla Henkes(Martin Luther University Halle-Wittenberg), Axel Hinke, Albrecht Kretzschmar(Roche (Switzerland)), Sylvie Lorenzen(Technical University of Munich), Marianne Sinn(Charité - Universitätsmedizin Berlin), Claudia Wickenhauser
Cited by 57
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k